Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.

Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE

Original Publication: Albany, N.Y. : Impact Journals

Biomarkers, Tumor* ; Gene Expression Regulation, Neoplastic*; Breast Neoplasms/*genetics ; Embryonic Stem Cells/*metabolism ; Octamer Transcription Factor-3/*genetics ; Transcription Factors/*genetics; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Combined Modality Therapy/methods ; Drug Resistance, Neoplasm/genetics ; Epithelial-Mesenchymal Transition/genetics ; Female ; Humans ; Kruppel-Like Factor 4 ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/metabolism ; Phenotype ; Prognosis ; Survival Analysis ; Tamoxifen/pharmacology ; Tamoxifen/therapeutic use

The transcription factors of embryonic stem cells, such as Oct4, Sox2, Nanog, Bmi1, and Klf4, are known to be associated with stemness, epithelial-mesenchymal transition and aggressive tumor behavior. This study was designed to evaluate the clinicopathological significance of their expression in breast cancer. Immunohistochemistry for Oct4, Sox2, Nanog, Bmi1, and Klf4 was performed in 319 cases of invasive breast cancer. The relationship between the expression of these markers and clinicopathologic features of the tumors, including breast cancer stem cell phenotype and epithelial-mesenchymal transition marker expression, and their prognostic value in breast cancer, were analyzed. Expression of Oct4 and Sox2 was commonly associated with high histologic grade and high Ki-67 index in the whole group and in the hormone receptor-positive subgroup. On the other hand, expression of Nanog, Bmi1, and Klf4 was inversely correlated with aggressive features of the breast cancer. Oct4 expression was associated with ALDH1 expression but not with epithelial-mesenchymal transition marker expression. In survival analysis, Oct4 expression was independently associated with poor prognosis in the whole group and in the hormone receptor-positive subgroup, but not in hormone receptor-negative subgroup. Particularly, Oct4 expression was associated with poor clinical outcome in patients with hormone receptor-positive breast cancer treated with tamoxifen. Our results indicate that Oct4 expression is associated with aggressive features, ALDH1 expression, tamoxifen resistance and poor clinical outcomes in hormone receptor-positive breast cancer, and thus may be useful as a predictive and prognostic marker in this subgroup of breast cancer.

Int J Clin Exp Med. 2015 Dec 15;8(12):22382-92. (PMID: 26885218)
Oncogene. 2016 Nov 3;35(44):5722-5734. (PMID: 27065334)
Cell. 2005 Sep 23;122(6):947-56. (PMID: 16153702)
Ann Surg. 2011 Jun;253(6):1165-71. (PMID: 21394007)
Mol Med Rep. 2015 Mar;11(3):1851-8. (PMID: 25420671)
Onco Targets Ther. 2016 Sep 06;9:5483-8. (PMID: 27660465)
J Exp Clin Cancer Res. 2016 May 25;35:84. (PMID: 27225481)
Mod Pathol. 2007 Apr;20(4):474-81. (PMID: 17334350)
Breast Cancer Res Treat. 2009 Jan;113(1):83-93. (PMID: 18228133)
Oncotarget. 2014 Nov 15;5(21):10803-15. (PMID: 25301732)
Cell Stem Cell. 2007 Nov;1(5):555-67. (PMID: 18371393)
Histopathology. 2014 Mar;64(4):494-503. (PMID: 24382260)
Ann Oncol. 2011 Aug;22(8):1736-47. (PMID: 21709140)
Biochem Biophys Res Commun. 2011 Aug 12;411(4):786-91. (PMID: 21798248)
Cell. 2008 May 16;133(4):704-15. (PMID: 18485877)
J Hematol Oncol. 2015 Mar 11;8:23. (PMID: 25879771)
Nat Genet. 2000 Apr;24(4):372-6. (PMID: 10742100)
Breast Cancer. 2014 Jan;21(1):96-101. (PMID: 22528804)
Oncotarget. 2014 Oct 30;5(20):9678-88. (PMID: 25127259)
Cell Stem Cell. 2008 Feb 7;2(2):123-34. (PMID: 18371433)
Cell Stem Cell. 2010 Jul 2;7(1):51-63. (PMID: 20621050)
Oncogene. 2011 May 5;30(18):2161-72. (PMID: 21242971)
Int J Mol Sci. 2014 Oct 28;15(11):19634-49. (PMID: 25353179)
BMC Cancer. 2014 Feb 24;14 :122. (PMID: 24559156)
Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
Nature. 2009 Jul 2;460(7251):118-22. (PMID: 19571885)
Oncogene. 2009 Aug 13;28(32):2894-902. (PMID: 19503094)
Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098)
BMC Cancer. 2014 Oct 28;14 :785. (PMID: 25348805)
Oncogene. 2014 May 15;33(20):2655-64. (PMID: 23770853)
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. (PMID: 12629218)
Breast Cancer Res Treat. 2014 Aug;147(1):39-49. (PMID: 25086633)
BMC Cancer. 2015 Mar 10;15:113. (PMID: 25879941)
Tumour Biol. 2016 Apr;37(4):4649-54. (PMID: 26508029)
Breast Cancer (Dove Med Press). 2015 Jul 15;7:183-91. (PMID: 26203276)
Breast Cancer. 2017 Mar;24(2):326-335. (PMID: 27300169)
Nat Rev Cancer. 2008 Oct;8(10):755-68. (PMID: 18784658)

Keywords: Oct4; breast cancer; cancer stem cell; prognosis; tamoxifen resistance

0 (Antineoplastic Agents, Hormonal)
0 (Biomarkers, Tumor)
0 (KLF4 protein, human)
0 (Kruppel-Like Factor 4)
0 (Octamer Transcription Factor-3)
0 (POU5F1 protein, human)
0 (Transcription Factors)
094ZI81Y45 (Tamoxifen)

Date Created: 20170420 Date Completed: 20180326 Latest Revision: 20220330

20240829

PMC5482656

10.18632/oncotarget.16750

28422735